4003 Background: An exploratory analysis of a randomized phase II study in HCC
comparing doxorubicin (D) alone to doxorubicin plus sorafenib (D+ S) showed a significant …

Context In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall
survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A …

Importance Previous communication has reported significant improvement in overall survival
(OS) when using doxorubicin plus sorafenib in the treatment of advanced hepatocellular …

Background Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care
for first-line systemic treatment of advanced hepatocellular carcinoma (HCC). Everolimus (E) …

Sorafenib, an oral multikinase inhibitor, shows efficacy in renal cell and hepatocellular
carcinoma (HCC) and is well tolerated when combined with doxorubicin in other solid …

Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C …

LBA1 Background: HCC is the 3rd cause of cancer death globally with most deaths
occurring within 1 year of diagnosis. No standard therapy exists for advanced HCC …

Until now, no effective systemic treatment options have been available for patients with
unresectable advanced hepatocellular carcinoma (HCC). In the Sorafenib Hepatocellular …

Background Hepatocellular carcinoma (HCC) is the fifth most common malignancy
worldwide. Unresectable disease patients have median survival of few months. There is a …

Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored
whether any specific subgroups of patients may gain more survival benefits from sorafenib …